Scott C Kogan Selected Research

promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein

12/2007	PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL.
10/2006	CCAAT/enhancer binding proteins alpha and epsilon cooperate with all-trans retinoic acid in therapy but differ in their antileukemic activities.
1/2006	Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia.
7/2003	Cooperation of cytokine signaling with chimeric transcription factors in leukemogenesis: PML-retinoic acid receptor alpha blocks growth factor-mediated differentiation.
2/2003	CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Scott C Kogan Research Topics

Disease

23	Leukemia 01/2021 - 04/2002
20	Neoplasms (Cancer) 01/2022 - 10/2005
14	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 02/2003
11	Acute Promyelocytic Leukemia 10/2018 - 04/2003
5	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021 - 07/2015
4	Lymphoma (Lymphomas) 01/2022 - 08/2006
4	Carcinogenesis 01/2014 - 08/2006
4	Genetic Translocation (Chromosomal Translocation) 03/2013 - 02/2003
4	Myeloproliferative Disorders (Myeloproliferative Disorder) 09/2009 - 01/2004
3	Myeloid Leukemia (Leukemia, Myelocytic) 03/2013 - 04/2003
2	Hemorrhage 10/2021 - 05/2021
2	Thromboembolism 05/2021 - 02/2019
2	Disease Progression 05/2006 - 06/2004
2	Hypersensitivity (Allergy) 06/2004 - 01/2004
1	B-Cell Leukemia (Leukemia, B Cell) 01/2022
1	Inflammation (Inflammations) 01/2022
1	Dysbiosis 01/2022
1	Lymphoid Leukemia 01/2022
1	Body Weight (Weight, Body) 01/2021
1	Glucocorticoid Receptor Deficiency 01/2020
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2020
1	Hematologic Neoplasms (Hematological Malignancy) 01/2020
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 02/2019
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2018
1	Myocardial Infarction 01/2018
1	Neoplasm Metastasis (Metastasis) 01/2014
1	Splenomegaly 10/2013
1	Neurofibromatosis 1 (Neurofibromatosis Type I) 02/2007
1	Acute Disease 10/2006

Drug/Important Bio-Agent (IBA)

11	Proteins (Proteins, Gene)FDA Link 01/2020 - 02/2003
6	Tretinoin (Retinoic Acid)FDA LinkGeneric 10/2016 - 04/2003
5	Oncogene Proteins (Oncogene Protein)IBA 01/2018 - 01/2006
5	Retinoic Acid Receptor alphaIBA 03/2013 - 02/2003
5	promyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinIBA 12/2007 - 02/2003
4	Pharmaceutical PreparationsIBA 05/2021 - 05/2006
4	CytokinesIBA 01/2021 - 07/2003
4	Transcription Factors (Transcription Factor)IBA 03/2013 - 07/2003
3	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 10/2018 - 02/2011
3	Small Interfering RNA (siRNA)IBA 12/2014 - 04/2011
3	DNA (Deoxyribonucleic Acid)IBA 02/2011 - 02/2005
2	Factor Xa InhibitorsIBA 10/2021 - 05/2021
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 03/2010
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2021 - 06/2004
2	Phosphotransferases (Kinase)IBA 01/2020 - 05/2006
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 05/2015 - 04/2003
2	Tyrosine Kinase InhibitorsIBA 04/2014 - 04/2003
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 10/2013 - 04/2006
2	MethyltransferasesIBA 02/2011 - 09/2008
2	Neurofibromin 1 (Neurofibromin)IBA 09/2008 - 02/2007
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 09/2008 - 10/2005
2	Sirolimus (Rapamycin)FDA Link 08/2008 - 08/2006
2	GTPase-Activating Proteins (GTPase-Activating Protein)IBA 02/2007 - 06/2004
2	CCAAT-Enhancer-Binding ProteinsIBA 04/2006 - 02/2003
1	Interleukin-10 (Interleukin 10)IBA 01/2022
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2022
1	SmokeIBA 01/2021
1	Interleukin-4 (Interleukin 4)IBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	Interleukin-8 (Interleukin 8)IBA 01/2021
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021
1	Mutant Proteins (Protein, Mutant)IBA 11/2020
1	A-factor (Streptomyces)IBA 10/2020
1	Cysteine (L-Cysteine)FDA Link 01/2020
1	GlucocorticoidsIBA 01/2020
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2020
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2020
1	2- (1H- indazol- 4- yl)- 6- (4- methanesulfonylpiperazin- 1- ylmethyl)- 4- morpholin- 4- ylthieno(3,2- d)pyrimidineIBA 01/2020
1	ArginaseIBA 11/2019
1	Antiphospholipid AntibodiesIBA 02/2019
1	Dietary IronIBA 01/2018
1	quizartinibIBA 04/2014
1	crenolanibIBA 04/2014
1	Tyrosine (L-Tyrosine)FDA Link 04/2014
1	UbiquitinIBA 01/2014
1	Ligases (Synthetase)IBA 01/2014
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 10/2013
1	Histone DemethylasesIBA 03/2013
1	ChromatinIBA 08/2011
1	Cyclin-Dependent Kinase Inhibitor p16IBA 04/2011
1	Renilla LuciferasesIBA 04/2011
1	Azacitidine (5 Azacytidine)FDA Link 02/2011
1	Choline (Choline Chloride)IBA 02/2011
1	Folic Acid (Vitamin M)FDA LinkGeneric 02/2011
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 09/2009
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 09/2009
1	Arsenic Trioxide (Trisenox)FDA Link 01/2009
1	Biological ProductsIBA 09/2008
1	O-(6)-methylguanineIBA 09/2008
1	Mechanistic Target of Rapamycin Complex 1IBA 08/2008
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 08/2008
1	Histone Deacetylases (Histone Deacetylase)IBA 12/2007
1	Eukaryotic Initiation Factor-4EIBA 08/2006
1	TOR Serine-Threonine KinasesIBA 08/2006
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 08/2006

Therapy/Procedure

13	Therapeutics 01/2018 - 01/2005
3	Drug Therapy (Chemotherapy) 04/2009 - 05/2006
1	Hematopoietic Stem Cell Transplantation 01/2021
1	Transplantation 01/2021
1	Cranial Irradiation 01/2011
1	Induction Chemotherapy 04/2009